- Company
- Celltrion receives CHMP positive opinion for 4 biosimilars
- by Chon, Seung-Hyun Dec 17, 2024 05:51am
- Celltrion announced on the 16th that the. European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorizations for its 4 biosimilar candidates. With the recommendations, Celltrion’s 4 biosimilar versions for Actemra, Eylea, Prolia, and Xgeva are expected to be approved in Europe. The bio
- Company
- Keytruda and Vyloy to transform gastric cancer treatment
- by Moon, sung-ho Dec 17, 2024 05:51am
- Metastatic gastric cancer has long been labeled as a drug-barren area on site. Various clinical studies have been conducted to develop new therapies for the area, but most have been unsuccessful. This is due to the tumor's heterogeneity, which makes it difficult to prove the efficacy of treatments. However, the recent introduction of immuno-o
- Company
- Soaring exchange rate causes pharma asset value to fluctuate
- by Kim, Jin-Gu Dec 16, 2024 05:53am
- The sharp rise in the won-dollar exchange rate in the aftermath of the impeachment and martial law has had a significant impact on the asset value of pharmaceutical and biotech companies. Companies with much foreign currency assets held in dollars have shown a significant increase in their asset value due to the high exchange rate, such as Sa
- Company
- Daiichi Sankyo appoints Sunjin Lee to head Enhertu BU
- by Eo, Yun-Ho Dec 16, 2024 05:52am
- Daiichi Sankyo Korea has appointed Sunjin Lee (47), a former executive director of Takeda Pharmaceuticals Korea, as the new head of Daiichi Sankyo. According to industry sources, Daiichi Sankyo recently made the appointment. Lee will succeed Mr. Hyun-Joo Lee (48), who has left to head ZP Therapeutics Korea. After working at Baxter Kor
- Company
- New PAH drug Winrevair to land in KOR next year
- by Eo, Yun-Ho Dec 13, 2024 05:52am
- The new pulmonary arterial hypertension drug ‘Winrevair’ is expected to be commercialized in Korea soon. According to industry sources, MSD Korea's Winrevair (sotatercept), the world's first symptomatic treatment for pulmonary arterial hypertension, recently passed the second approval-reimbursement linkage evaluations. The drug’s forma
- Company
- "Confirmed long-term Tx effects of Camzyos…new oHCM Tx"
- by Son, Hyung Min Dec 13, 2024 05:51am
- "In a clinical study spanning three years, Camzyos has demonstrated consistent patient symptom management and safety in many patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its proven efficacy in long-term treatment, it is expected that many patients with oHCM can significantly improve their quality of life through this t
- Company
- NeuroBiogen enters into Binding Term Sheet with US Company
- by Lee, Seok-Jun Dec 12, 2024 05:50am
- Scilex Holding Company, a Nasdaq-listed company, announced that d a binding Term Sheet&160;had been signed between NeuroBiogen, a Korean company specializing in innovative new drugs, and Scilex Bio, a controlling interest of joint venture by Scilex Holding Company on December 10th, local time. Under the terms of the agreement, Scilex Bio
- Company
- 'Effective in Asian patients' Leclaza vs Tagrisso comb
- by Son, Hyung Min Dec 12, 2024 05:49am
- Leclaza plus Rybrevant and Tagrisso plus platinum-based chemotherapy have shown consistent effects in Asian patients. The effects of the combination therapy of Leclaza and Tagrisso, which are non-small cell lung cancer (NSCLC) treatments, have been unveiled at the European Society for Medical Oncology (ESMO) Asia Congress 2024. ESMO Asia Con
- Company
- Merck Biopharma Korea and LG Chem will comarket Glucophage
- by Whang, byung-woo Dec 12, 2024 05:49am
- Merck Biopharma Korea announced on the 11th that it has signed a partnership agreement with LG Chem to jointly sell Glucophage (metformin hydrochloride), a treatment for type 2 diabetes, in Korea.&160; Under the agreement, LG Chem will distribute Glucophage to healthcare providers in Korea starting January 1, 2025. Merck Biopharma Kore
- Company
- 'Lalaola' wins 2024 Pharma Industry ad grand prize
- by Son, Hyung Min Dec 11, 2024 05:54am
- The winner of the 2024 pharmaceutical and biotechnology industry advertising·PR awards has been announced. Yuhan's 'Lalaola' won the Grand Prize in the advertising category, and Amgen Korea's 'Blue Wish campaign' won the Grand Prize in the PR category. On December 10, Dailypharm (Publisher: Lee Jeong Seok) hosted the '2024 Korean Pharmaceut
